Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1820 - A Phase Ib study of the safety and efficacy of atezolizumab (atezo) + bevacizumab (bev) + cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Johanna Bendell

Citation

Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246

Authors

J. Bendell1, C. Lieu2, K.P.S. Raghav3, G. Argilés4, A. Cubillo5, X. Qu6, Y. Yan6, M. Merchant7, H. Zeuner8, J.D. Gallo8, N.H. Segal9

Author affiliations

  • 1 Drug Development Unit Nashville, Sarah Cannon Research Institute, 37203 - Nashville/US
  • 2 Division Of Medical Oncology, University of Colorado, Denver/US
  • 3 Department Of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston/US
  • 4 Department Of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology VHIO, Barcelona/ES
  • 5 Oncología Médica, Servicio de Oncología Médica HM CIOCC, Madrid/ES
  • 6 Oncology Biomarker Development, Genentech, Inc., South San Francisco/US
  • 7 Translational Oncology, Genentech, Inc., South San Francisco/US
  • 8 Product Development Oncology, F. Hoffmann-La Roche, Ltd., Basel/CH
  • 9 Department Of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1820

Background

mCRC is a non-immunogenic tumour type with poor response to checkpoint inhibitors, hypothetically due to low tumour T-cell levels and incomplete blockade of MAPK-mediated growth factor signalling. Combining the anti-tumour immunity effects of the anti–PD-L1 Ab (atezo), MEK inhibitor (cobi) and anti-VEGF Ab (bev) in pts with mCRC may improve response. Atezo enhances T-cell priming/activation, cobi decreases tumour growth and increases tumour antigen presentation via MHC I and bev increases T-cell infiltration. Therefore, bev + atezo + cobi may enhance immune recognition of mCRC. This report is the primary analysis of a Phase Ib study of this combination.

Methods

This study assessed the safety and activity of atezo (840 mg q2w IV) + bev (5 mg/kg q2w IV) + cobi (60 mg qd 21 on/7 off oral) in pts with mCRC who progressed on ≥ 1 prior line of treatment (tx) containing 5-FU and oxaliplatin/irinotecan. After safety run-in, dose-expansion and biopsy cohorts were enrolled. The primary objective was to assess safety.

Results

In the primary analysis (Sep 21, 2018, cutoff), 49 pts were evaluated. Median safety follow-up was 7.8 mo (range, 1.4-25.4 mo). Median prior lines of tx was 2 (range, 1-7). 33 pts (67%) had RAS-mutant tumours. 45 pts (92%) had microsatellite stable disease; 4 pts (8%) had unknown microsatellite status. 48 pts (98%) had tx-related AEs (TRAEs), 30 pts (61%) had G3-5 TRAEs and 1 pt (2%) had bev-related G5 GI necrosis. AEs led to tx withdrawal in 9 pts (18%). Most common AEs were diarrhoea (78%), acneiform dermatitis (51%), fatigue (49%), rash (41%) and CPK increase (35%). Confirmed ORR was 8% in the overall population. See Table for activity by tx line and RAS status.Table:

603P

2L therapy (n = 25)3L+ therapy (n = 24)Overall (N = 49)
Confirmed response per RECIST 1.1, n (%)a2 (8%)2 (8%)4 (8%)
mPFS (range), moa5.5 (3.6-9.4)5.8(2.4-9.0)5.5 (3.6-7.5)
mOS (range), moNE(11.7-NE)11.8 (8.7-21.8)11.8 (9.0-21.8)
RAS mutant (n = 33)RAS wild-type/ unknown (n = 16)Pb HR (95% CI)
DCR, n (%)c (95% CI)12 (36) (20, 55)5 (31) (11, 59)
mPFS, mo (95% CI)5.8 (3.6, 11.6)3.6 (2.6, 7.3)0.05 2.2 (1.1, 4.5)
mOS, mo (95% CI)21.8 (9.0, NE)9.1 (3.6, 14.5)0.34 1.8 (0.6, 5.5)

Ab, antibody; DCR, disease control rate; HR, hazard ratio; mPFS, median progression-free survival; mOS, median overall survival; NE, not estimable; RECIST, Response Evaluation Criteria in Solid Tumours.

a

Investigator assessed.

b

P values not controlled for type I error and are descriptive only.

c

At 4 mo.

Conclusions

Atezo + bev + cobi had an acceptable safety profile with manageable AEs with improved activity over that reported with SOC in 2L+ mCRC. A greater benefit trend was seen in pts with a RAS mutation vs wild-type tumours.

Clinical trial identification

NCT02876224.

Editorial acknowledgement

Chris Lum, PhD, of Health Interactions, funded by F. Hoffmann-La Roche, Ltd.

Legal entity responsible for the study

F. Hoffmann-La Roche, Ltd.

Funding

F. Hoffmann-La Roche, Ltd.

Disclosure

J. Bendell: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Gilead; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche/Genentech; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Five Prime; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: MedImmune; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Celgene; Research grant / Funding (institution): EMD Serono; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Taiho; Advisory / Consultancy, Research grant / Funding (institution): Macrogenics; Advisory / Consultancy, Research grant / Funding (institution): GSK; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: OncoMed; Advisory / Consultancy, Research grant / Funding (institution): LEAP; Advisory / Consultancy, Research grant / Funding (institution): TG Therapeutics; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BI; Advisory / Consultancy, Research grant / Funding (institution): Daiichi Sankyo; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Incyte; Advisory / Consultancy, Research grant / Funding (institution): Apexigen; Research grant / Funding (institution): Koltan; Research grant / Funding (institution): SynDevRex; Research grant / Funding (institution): Forty Seven; Research grant / Funding (institution): AbbVie; Advisory / Consultancy, Research grant / Funding (institution): Array; Research grant / Funding (institution): Onyx; Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Celldex; Research grant / Funding (institution): Agios; Research grant / Funding (institution): Cytomx; Research grant / Funding (institution): Nektar; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: ARMO; Research grant / Funding (institution): Boston Biomedical; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Ipsen; Advisory / Consultancy, Research grant / Funding (institution): Merrimack; Research grant / Funding (institution): Tarveda; Research grant / Funding (institution): Tyrogenex; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Oncogenex; Research grant / Funding (institution): Marshall Edwards; Research grant / Funding (institution): Pieris; Research grant / Funding (institution): Mersana; Research grant / Funding (institution): Calithera; Research grant / Funding (institution): Blueprint; Research grant / Funding (institution): Evelo; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: FORMA; Research grant / Funding (institution): Jacobio; Research grant / Funding (institution): Effector; Research grant / Funding (institution): Novocare; Research grant / Funding (institution): Arrys; Research grant / Funding (institution): Tracon; Research grant / Funding (institution): Sierra; Advisory / Consultancy, Research grant / Funding (institution): Arch Oncology; Advisory / Consultancy, Research grant / Funding (institution): Prelude Oncology; Research grant / Funding (institution): Unum Therapeutics; Research grant / Funding (institution): Vyriad; Research grant / Funding (institution): Harpoon; Research grant / Funding (institution): ADC; Advisory / Consultancy, Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Millennium; Research grant / Funding (institution): Imclone; Research grant / Funding (institution): Acerta Pharma; Research grant / Funding (institution): Rgenix; Research grant / Funding (institution): Bellicum; Advisory / Consultancy: Phoenix Bio; Advisory / Consultancy: Cyteir; Advisory / Consultancy: Molecular Partners; Advisory / Consultancy: Innate; Advisory / Consultancy: Torque; Advisory / Consultancy: Tizona; Advisory / Consultancy: Janssen; Advisory / Consultancy: Tolero; Advisory / Consultancy: TD2 (Translational Drug Development); Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: Moderna Therapeutics; Advisory / Consultancy: Tanabe Research Laboratories; Advisory / Consultancy: Beigene; Advisory / Consultancy: Continuum Clinical; Advisory / Consultancy: Agios. C. Lieu: Honoraria (self): Foundation Medicine. K.P.S. Raghav: Honoraria (self): Genentech, Inc.; Honoraria (self): Bayer, Inc.; Travel / Accommodation / Expenses: Tracon, Inc. G. Argilés: Full / Part-time employment: VHIO; Research grant / Funding (institution): Bayer; Research grant / Funding (self): Spains Society Against Cancer; Honoraria (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Travel / Accommodation / Expenses: Amgen; Honoraria (self), Travel / Accommodation / Expenses: Merck Serono; Honoraria (self): BMS; Honoraria (self), Travel / Accommodation / Expenses: Servier; Honoraria (self), Travel / Accommodation / Expenses: Bayer. A. Cubillo: Advisory / Consultancy, Research grant / Funding (institution): Servier; Research grant / Funding (institution): Adacap; Research grant / Funding (institution): Merck; Advisory / Consultancy: Amgen. X. Qu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Genentech Inc. Y. Yan: Shareholder / Stockholder / Stock options, Full / Part-time employment: Genentech/Roche. M. Merchant: Full / Part-time employment: Genentech/Roche. H. Zeuner: Full / Part-time employment: Roche. J.D. Gallo: Shareholder / Stockholder / Stock options, Full / Part-time employment: Genentech Inc. N.H. Segal: Advisory / Consultancy, Research grant / Funding (institution): Roche/Genentech; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy, Research grant / Funding (institution): MedImmune/AstraZeneca; Research grant / Funding (institution): Incyte; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Pieris; Advisory / Consultancy: PsiOxus; Advisory / Consultancy: Synlogic; Advisory / Consultancy: Aduro; Advisory / Consultancy: Kyn Therapautics; Advisory / Consultancy: Pure Tech Ventrures; Advisory / Consultancy: Horizon Pharma; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Gritstone Oncology; Advisory / Consultancy: Chugai; Advisory / Consultancy: TRM Oncology; Advisory / Consultancy: IFM Therapeutics; Advisory / Consultancy: Cstone Pharmaceuticals.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.